Navigation Links
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Date:2/6/2008

Data also showed differences in gastrointestinal and lipid effects between

REYATAZ/ritonavir and lopinavir/ritonavir among study population

PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the CASTLE study, in which 300 mg of once-daily REYATAZ(R) (atazanavir sulfate) taken with 100 mg of ritonavir (REYATAZ/r) showed similar antiviral efficacy to twice-daily lopinavir 400 mg and ritonavir 100 mg (lopinavir/r) in previously untreated adult HIV-1 infected patients at 48 weeks, as part of HIV combination therapy. In this study, 78 percent of the 440 patients in the REYATAZ/r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than 50 copies/mL) at 48 weeks, compared with 76 percent of the 443 patients in the lopinavir/r arm.

CASTLE is the first large-scale, open-label, randomized study designed to demonstrate the non-inferiority of REYATAZ/r to lopinavir/r in previously untreated HIV-1 infected adult patients. Data from the CASTLE study were presented for the first time at the 15th Conference on Retroviruses and Opportunistic Infections (CROI) this week in Boston, Mass.

"The CASTLE study provides important additional data to inform the use of a once-daily regimen including REYATAZ and ritonavir in antiretroviral-naive HIV-infected patients," said Jean-Michel Molina, M.D., Hopital Saint Louis, Paris, France. "When choosing a treatment in previously untreated patients it is important to ensure antiviral activity as well as tolerability to optimize the management of HIV infection over the long term."

The most common grade 2-4 adverse events occurring in greater than or equal to three percent of patients
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
2. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
3. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Inverseon Announces Positive Phase IIa Asthma Study
6. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
7. Study Says Allergy Shots Help Children, Reduce Health Care Costs
8. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
9. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
10. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, announced that Edwards, ... served as an expert panelist at the invitation of ... Health to discuss medical device innovation at its hearing, ... Evidence Development and Communication." "Edwards has five ...
(Date:7/22/2014)... 22, 2014  Jazz Pharmaceuticals plc (Nasdaq: ... 2014 second quarter financial results on Tuesday, August 5, ... management will host a live audio webcast immediately following ... provide a business and financial update and discuss second ... access the live audio webcast via the Investors & ...
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
Breaking Medicine Technology:Edwards' CEO Invited To Address Congress On Opportunities To Revitalize Medical Device Innovation 2Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3
... ) announced today that its Board of Directors approved a regular cash dividend payment of $0.0425 per share. , ... , , ... ... The dividend is payable on May 7, 2010 to shareholders of record as of April 6, 2010 . , ...
... ... , ... ... SILVER SPRING, Md. , March 22 FDA is recommending that healthcare practitioners temporarily suspend use of ...
Cached Medicine Technology:Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 2Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 3Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk 4
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... are obese during pregnancy may be more likely to have ... "We found that, compared with children born from mothers ... during pregnancy had up to 20 to 30 percent higher ... assistant professor of pediatrics at Children,s Hospital of Pittsburgh. ...
(Date:7/22/2014)... (WASHINGTON, July 22, 2014) The American Society of ... Vanderbilt University School of Medicine, and Robert P. Hebbel, ... the 2014 Ernest Beutler Lecture and Prize for their ... disease. , The Ernest Beutler Lecture, named for the ... and physician-scientist for more than 50 years, is a ...
(Date:7/22/2014)... a member of the Clean Plate Club you eat ... not alone! A new Cornell University study shows that ... puts on his or her plate. "If you ... says Brian Wansink Ph.D., author of the forthcoming book, Slim ... Food and Brand Lab. , Wansink and co-author Katherine Abowd ...
(Date:7/22/2014)... Dr. Ross Feldman says women are often in the dark. ... disease, however, data has shown that post-menopausal women are just ... less likely to be adequately diagnosed and treated. New research ... British Journal of Clinical Pharmacology brings to light a ... identify which women are more prone to heart disease. , ...
(Date:7/22/2014)... D.C. (PRWEB) July 22, 2014 ... “Ensuring Seniors Access to Local Pharmacies Act of ... Medicare Part D would undermine the availability of ... spending by $21 billion over the next 10 ... Company released by the Pharmaceutical Care Management Association ...
Breaking Medicine News(10 mins):Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:Gene variant identified as a heart disease risk factor for women 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... LONDON, November 11 Extensive research conducted by the,Imperial ... on the Simbionix PROcedure Rehearsal Studio(TM), was awarded a,Magna ... in Lisbon, Portugal. , The ... world,s first patient specific system to enable clinicians to ...
... ... the home or office using methods and products that are government-approved, but that won,t harm ... ... present The Natural Flu Protection Kit, the first product to emerge from the company’s partnership ...
... ... , ... November 11, 2009 -- HEALTHeCAREERS , North America’s premier healthcare Network, is advertising ... the medical industry continues to be one of the few bright spots in the ...
... ... and the Beyond the Box team can assist seniors and their loved ones with the ... ... relocation and design firm, Beyond the Box , is pleased to announce its new ...
... The following statement can be attributed to Steven ... the American Chemistry Council (ACC) regarding the study published ... the Risk of Self-Reported Male Sexual Dysfunction," by D. ... study of occupational exposure to bisphenol A (BPA) among ...
... School of Public Health researchers will present Nov. 11 ... Health Association,s annual meeting in Philadelphia, including a study ... large-scale worksite wellness program. Additional public health ... Does faith affect how Southern African-American women use ...
Cached Medicine News:Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 2Health News:Research on Simbionix PROcedure Rehearsal Software Awarded Magna Cum Laude Prize at CIRSE 2009 3Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 2Health News:Green Living Expert Annie B. Bond's Natural Flu Protection Kit 3Health News:Healthcare Web Site Boasts Thousands of Jobs in a Down Economy 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 2Health News:Relocation Specialists Beyond the Box Team With Nurse to Help Facilitate Senior Moves 3Health News:Findings from New Study on Occupational Exposure to BPA of Limited Relevance to Consumers 2Health News:Worksite wellness programs may reduce employee absenteeism 2
Micro suture forceps....
Mini blades....
... M520 OH3 is a smart ... performance available on the market ... stand. The Leica M520 OH3 ... greatest range of movement and ...
Operating microscope with motorized zoom and variable focus up to 405 mm....
Medicine Products: